A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)

Trial Profile

A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Carotuximab (Primary) ; Pazopanib
  • Indications Haemangiosarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TAPPAS
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to a TRACON Pharmaceuticals media release, the study continues to enroll well, and is on track to deliver key interim data in mid-2018.
    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, an interim analysis is planned to occur upon the occurrence of 40 events in approximately 70 patients.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top